Literature DB >> 26912663

A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.

Saumya M Sankaran1, Alex W Wilkinson1, Joshua E Elias2, Or Gozani3.   

Abstract

The readout of histone modifications plays a critical role in chromatin-regulated processes. Dimethylation at Lys-36 on histone H3 (H3K36me2) is associated with actively transcribed genes, and global up-regulation of this modification is associated with several cancers. However, the molecular mechanism by which H3K36me2 is sensed and transduced to downstream biological outcomes remains unclear. Here we identify a PWWP domain within the histone lysine methyltransferase and oncoprotein NSD2 that preferentially binds to nucleosomes containing H3K36me2. In cells, the NSD2 PWWP domain interaction with H3K36me2 plays a role in stabilizing NSD2 at chromatin. Furthermore, NSD2's ability to induce global increases in H3K36me2 via its enzymatic activity, and consequently promote cellular proliferation, is compromised by mutations within the PWWP domain that specifically abrogate H3K36me2-recognition. Together, our results identify a pivotal role for NSD2 binding to its catalytic product in regulating its cellular functions, and suggest a model for how this interaction may facilitate epigenetic spreading and propagation of H3K36me2.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  chromatin; chromatin modification; chromatin regulation; histone methylation; histone modification

Mesh:

Substances:

Year:  2016        PMID: 26912663      PMCID: PMC4861420          DOI: 10.1074/jbc.M116.720748

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15).

Authors:  Roberto Rosati; Roberta La Starza; Angelo Veronese; Ana Aventin; Christine Schwienbacher; Teresa Vallespi; Massimo Negrini; Massimo F Martelli; Cristina Mecucci
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

2.  BS69/ZMYND11 reads and connects histone H3.3 lysine 36 trimethylation-decorated chromatin to regulated pre-mRNA processing.

Authors:  Rui Guo; Lijuan Zheng; Juw Won Park; Ruitu Lv; Hao Chen; Fangfang Jiao; Wenqi Xu; Shirong Mu; Hong Wen; Jinsong Qiu; Zhentian Wang; Pengyuan Yang; Feizhen Wu; Jingyi Hui; Xiangdong Fu; Xiaobing Shi; Yujiang Geno Shi; Yi Xing; Fei Lan; Yang Shi
Journal:  Mol Cell       Date:  2014-09-25       Impact factor: 17.970

3.  NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

Authors:  Alex J Kuo; Peggie Cheung; Kaifu Chen; Barry M Zee; Mitomu Kioi; Josh Lauring; Yuanxin Xi; Ben Ho Park; Xiaobing Shi; Benjamin A Garcia; Wei Li; Or Gozani
Journal:  Mol Cell       Date:  2011-11-18       Impact factor: 17.970

4.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Authors:  M Chesi; E Nardini; R S Lim; K D Smith; W M Kuehl; P L Bergsagel
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

5.  Biased chromatin signatures around polyadenylation sites and exons.

Authors:  Noah Spies; Cydney B Nielsen; Richard A Padgett; Christopher B Burge
Journal:  Mol Cell       Date:  2009-10-23       Impact factor: 17.970

6.  A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome.

Authors:  Keisuke Nimura; Kiyoe Ura; Hidetaka Shiratori; Masato Ikawa; Masaru Okabe; Robert J Schwartz; Yasufumi Kaneda
Journal:  Nature       Date:  2009-05-31       Impact factor: 49.962

7.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

8.  The site-specific installation of methyl-lysine analogs into recombinant histones.

Authors:  Matthew D Simon; Feixia Chu; Lisa R Racki; Cecile C de la Cruz; Alma L Burlingame; Barbara Panning; Geeta J Narlikar; Kevan M Shokat
Journal:  Cell       Date:  2007-03-09       Impact factor: 41.582

9.  Epigenome microarray platform for proteome-wide dissection of chromatin-signaling networks.

Authors:  Dennis J Bua; Alex J Kuo; Peggie Cheung; Chih Long Liu; Valentina Migliori; Alexsandra Espejo; Fabio Casadio; Christian Bassi; Bruno Amati; Mark T Bedford; Ernesto Guccione; Or Gozani
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

10.  Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma.

Authors:  Ana R Grosso; Ana P Leite; Sílvia Carvalho; Mafalda R Matos; Filipa B Martins; Alexandra C Vítor; Joana M P Desterro; Maria Carmo-Fonseca; Sérgio F de Almeida
Journal:  Elife       Date:  2015-11-17       Impact factor: 8.140

View more
  27 in total

Review 1.  The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Authors:  Richard L Bennett; Alok Swaroop; Catalina Troche; Jonathan D Licht
Journal:  Cold Spring Harb Perspect Med       Date:  2017-06-01       Impact factor: 6.915

2.  Identification of a novel leukemic-specific splice variant of DNMT3B and its stability.

Authors:  Prachi Singh; Sarvagalla Sailu; Elango Palchamy; Mohane Selvaraj Coumar; Sudhakar Baluchamy
Journal:  Med Oncol       Date:  2017-07-20       Impact factor: 3.064

3.  Screening for histone codebreakers.

Authors:  Mark T Bedford
Journal:  J Biol Chem       Date:  2018-08-31       Impact factor: 5.157

4.  High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.

Authors:  Nathan P Coussens; Stephen C Kales; Mark J Henderson; Olivia W Lee; Kurumi Y Horiuchi; Yuren Wang; Qing Chen; Ekaterina Kuznetsova; Jianghong Wu; Sirisha Chakka; Dorian M Cheff; Ken Chih-Chien Cheng; Paul Shinn; Kyle R Brimacombe; Min Shen; Anton Simeonov; Madhu Lal-Nag; Haiching Ma; Ajit Jadhav; Matthew D Hall
Journal:  J Biol Chem       Date:  2018-06-26       Impact factor: 5.157

Review 5.  H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.

Authors:  David S Rogawski; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2016-08-22       Impact factor: 3.808

Review 6.  Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

Authors:  Brian M Linhares; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2020-06-19       Impact factor: 3.808

7.  Substrate docking-mediated specific and efficient lysine methylation by the SET domain-containing histone methyltransferase SETD7.

Authors:  Haiyang Liu; Zhiwei Li; Qingqing Yang; Wei Liu; Jun Wan; Jianchao Li; Mingjie Zhang
Journal:  J Biol Chem       Date:  2019-07-19       Impact factor: 5.157

8.  Characterization of H3.3K36M as a tool to study H3K36 methylation in cancer cells.

Authors:  Saumya M Sankaran; Or Gozani
Journal:  Epigenetics       Date:  2017-12-11       Impact factor: 4.528

Review 9.  Histone lysine methyltransferases in biology and disease.

Authors:  Dylan Husmann; Or Gozani
Journal:  Nat Struct Mol Biol       Date:  2019-10-03       Impact factor: 15.369

Review 10.  The interplay between DNA and histone methylation: molecular mechanisms and disease implications.

Authors:  Yinglu Li; Xiao Chen; Chao Lu
Journal:  EMBO Rep       Date:  2021-04-12       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.